Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 60 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

17%

10 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

21 recruiting

Enrollment Performance

Analytics

N/A

20(52.6%)

Phase 4

8(21.1%)

Phase 1

7(18.4%)

Phase 3

2(5.3%)

Phase 2

1(2.6%)

38Total

N/A(20)

Phase 4(8)

Phase 1(7)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials

NCT07841132Not ApplicableNot Yet Recruiting

CEST-PROTECT: Proximal Flow Control With a Balloon Guide Catheter Plus Distal Embolic Protection: a Randomised, Open-label Trial Evaluating Cerebral Protection Techniques

Role: collaborator

NCT06358209Not ApplicableRecruiting

Safety and Efficacy of Ventricular Irrigation for Ventriculitis

Role: collaborator

NCT07090941Not ApplicableRecruiting

EVT in Acute Basilar Artery Occlusion With Large Infarction Core

Role: collaborator

NCT07543263Recruiting

An Artificial Intelligence System for Multimodal, Multi-class Diagnosis of Pancreatic Cystic Lesions Based on Endoscopic Ultrasonography

Role: collaborator

NCT07761507Not ApplicableRecruiting

Transcutaneous Auricular Vagus Nerve Stimulation for Recovery of Consciousness After Surgery for Spontaneous Intracerebral Hemorrhage

Role: collaborator

NCT05965687Phase 3Completed

Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)

Role: collaborator

NCT06331923Not ApplicableCompleted

Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients With Diabetes

Role: collaborator

NCT07111572Recruiting

Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis

Role: collaborator

NCT07111273Recruiting

DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis

Role: collaborator

NCT07466251Phase 4Not Yet Recruiting

PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke

Role: collaborator

NCT06902740Phase 4Recruiting

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

Role: collaborator

NCT06711016Not ApplicableRecruiting

Target-directed Management of Cerebral Oxygenation in Patients After Receiving ECPR

Role: collaborator

NCT07413068Recruiting

Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis

Role: collaborator

NCT07495111Not ApplicableRecruiting

Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis

Role: collaborator

NCT06284642Phase 4Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

Role: collaborator

NCT07444099Not ApplicableEnrolling By Invitation

Early Postoperative Intervention in Gastric Cancer Patients

Role: collaborator

NCT07402135Not ApplicableNot Yet Recruiting

Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis

Role: collaborator

NCT07381192Recruiting

An Artificial Intelligence System for Multimodal, Multi-class Diagnosing Solid Pancreatic Lesions Based on Endoscopic Ultrasound

Role: collaborator

NCT07379268Recruiting

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379255Recruiting

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Role: collaborator